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ABSTRACT
Posterior reversible encephalopathy syndrome (PRES) is a clinical-radiological entity with many causes. The primary abnormality is cerebral 
vasogenic oedema. Here we describe the management of five patients with PRES syndrome who presented to our hospital.
LEARNING POINTS
• Posterior reversible encephalopathy syndrome (PRES) presents with cerebral vasogenic oedema. 
• PRES resolves when blood pressure is controlled.
• Patients with a history of autoimmune disorder who present with confusion may have PRES.
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INTRODUCTION
Posterior reversible encephalopathy syndrome (PRES) is a clinical-radiological entity that was well described by Hinchey in 1996[1]. It has 
different names, but PRES is now the accepted term[2,3]. PRES has many causes, but the primary abnormality is cerebral vasogenic oedema[1,2]. 
Here we describe the management of five patients with PRES who presented to our hospital (Table 1).
CASE PRESENTATIONS
Case 1: PRES after immunosuppression in a patient with systemic lupus erythematosus
A 34-year-old woman with systemic lupus erythematosus (SLE) and lupus nephritis class IV was started on cyclophosphamide and rituximab 
in addition to IV methylprednisolone. After the second dose of cyclophosphamide, she developed generalized tonic-clonic seizures associated 
with headache and decreased vision, with high blood pressure of 190/100 mmHg. MRI findings showed a multifocal, irregular patchy area 
of high signal intensity in the parietal-occipital cortical and subcortical areas bilaterally, which was consistent with PRES (Fig. 1). The blood 
pressure and seizures were successfully managed, and the patient was discharged home after 6 days.
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Case 2: PRES after immunosuppression in a patient with SLE
A 23-year-old woman was diagnosed with lupus nephritis and refractory autoimmune haemolytic anaemia. Two weeks after initiation of 
cyclophosphamide and rituximab therapy in addition to IV methylprednisolone, she presented to the emergency department with tonic-
colonic convulsions, high blood pressure and worsening kidney function. The patient required intubation. MRI of the brain showed lesions 
typical of PRES, as in Case 1. The patient improved dramatically after the high blood pressure and seizures were brought under control. 
Case 3: PRES after immunosuppression in another patient with SLE
A 41-year-old woman with lupus nephritis presented to the emergency department with a history of convulsions and high blood pressure 
2 weeks after receiving pulse methylprednisolone followed by mycophenolate for the lupus nephritis. The patient required intubation 
and haemodialysis. MRI of the brain showed lesions typical of PRES, as in Case 1. She was treated with antihypertensive medications and 
antiepileptics with complete resolution of her symptoms. She was extubated after 2 days and discharged home after 16 days.
Case 4: PRES after pulse methylprednisolone therapy in a patient with SLE 
A 29-year-old woman with known SLE on conventional treatment including hydroxychloroquine and azathioprine, presented to the 
emergency department with fever, headache and pancytopenia. Investigations showed she had Epstein-Barr virus (EBV). Antibiotics and 
pulse steroids were administered for her SLE flare. However, she experienced seizures 3 days later. MRI of the brain indicated PRES, and the 
patient was transferred to the ICU. She developed diffuse alveolar haemorrhage (DAH) and later haemophagocytic lymphocytosis (HLH) 
which made treatment more difficult. The patient recovered but required extensive rehabilitation.
Case 5: PRES in a postpartum woman
A 41-year-old woman was transferred to the emergency from another hospital because of postpartum haemorrhage after a normal vaginal 
delivery. She presented with sudden impaired vision and left-sided weakness associated with high blood pressure. She was referred to 
rheumatology services for possible vasculitis, but vasculitis and other connective tissue diseases were excluded. MRI of the brain revealed a 
typical picture of PRES, as in Case 1. The patient responded well after her blood pressure was controlled, and all symptoms resolved. 
DISCUSSION 
PRES is a life-threatening condition which is characterized by symmetrical involvement of posterior white matter. It usually presents with 
neurological impairments such as seizure, altered mental status, headache and visual disturbance [2] with typical MRI findings of hyperintense 
lesions on FLAIR images in the parietal-occipital and posterior frontal cortical and subcortical white matter. Less commonly, the brainstem, 
basal ganglia and cerebellum are involved. Atypical imaging showing contrast enhancement, haemorrhage and restricted diffusion on 
Figure 1. Brain MRI showing high signal intensity in the parietal-occipital cortical 
and subcortical areas bilaterally
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MRI has also been reported[4]. The epidemiology of PRES is unknown but the condition normally occurs in young to middle-aged adults 
with a marked female predominance[5]. The pathophysiology of PRES remains elusive. However, it has been suggested that compromised 
cerebrovascular autoregulation due to acute hypertension may play a pivotal role. Accordingly, impaired cerebrovascular regulation 
may lead to arteriole leakage and cerebral vasogenic oedema[2]. The extensive use of immunosuppressive therapy (methylprednisolone, 
dexamethasone, cyclosporine and cyclophosphamide)[2] and the autoimmune nature of rheumatological diseases including SLE may render 
patients more vulnerable to developing PRES over the course of the disease[6].
We describe five cases of PRES, four of which had a background of SLE, with the other case being postpartum. Four of our five patients 
required mechanical ventilation, which is higher than reported in the literature, where ventilation was needed in 35%–40% of patients with 
PRES[7]. 
All four SLE patients were female and developed PRES after the initiation of immunosuppression therapy, mainly pulsed methylprednisolone; 
Cases 1 and 2 had also received a combination of cyclophosphamide and rituximab. The most common presentation of PRES is seizure 
(74%–92% of patients), followed by encephalopathy (28%–92%), headaches (26%–83%) and visual disturbances (20%–63%)[8], as also seen 
in our series, where four of the five patients presented with seizure. All our patients also reported headache and impaired vision, which 
is much higher than normally reported. Case 5 developed left-sided weakness as well. The most common associated sign is high blood 
pressure (53%–91.7%)[9], which was seen in all our patients. The main management of PRES consists of blood pressure control, treatment of 
associated seizures and removal of the causative agent[10].
It is uncommon for patients to develop recurrent PRES[11, 12] and very rare for it to occur more than twice, but two of our five patients had 
recurrent PRES, which might have been due non-compliance with medications together with the progressive nature of the lupus in some 
patients.
Case 1 Case 2 Case 3 Case 4 Case 5
Age, years 34 23 41 29 41
Sex Female Female Female Female Female 
Main presentation 
Headache impaired
 vision 
Convulsion and high 
blood pressure 
Headache, vomiting, 
convulsions and 
high blood pressure
Headache 
Convulsions and 
high blood pressure
Seizures
Headache impaired
 vision 
High blood pressure 
Left-sided weakness 
Medical illness Lupus nephritis 
Lupus nephritis and 
autoimmune haemolytic
anaemia 
Lupus nephritis 
Systemic lupus 
erythematosus 
Postpartum vaginal 
bleeding 
Previous medication 
Cyclophosphamide 
and rituximab with pulse 
methylprednisolone 
Cyclophosphamide and 
rituximab with pulse 
methylprednisolone
Pulse 
methylprednisolone
Pulse 
methylprednisolone 
None 
Required ICU
 management and 
mechanical ventilation 
Yes Yes Yes Yes No 
Duration of hospital 
stay 
6 Days 16 Days 15 Days 20 Days 6 Days
Previous history of 
PRES
Yes (3 times) No No Yes (3 times) No
Table 1. Patients with posterior reversible encephalopathy syndrome (PRES) treated in our hospital
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CONCLUSION 
The differential diagnosis of a patient who presents with altered mental status, headache or seizure should include PRES, especially if they 
have a rheumatological disease treated with immunosuppression. This is a significant point as symptoms of PRES can mimic flare or active 
disease in a patient with a rheumatological illness, but the management is entirely different. 
